Anivive Lifesciences, a Long Beach, CA-based software-driven pet health company, secured $20M in funding.
Leonid Capital Partners made the investment.
The company intends to use the funds to bolster its research programs, expand its manufacturing capabilities, and drive commercialization of its canine vaccine for Valley fever, the first-ever antifungal vaccine.
Led by Dylan Balsz, CEO, Anivive is a pet pharmaceutical company that uses technology driven strategies to create novel, affordable healthcare solutions for pets. Through a proprietary AI platform, Anivive accelerates drug discovery and development by repurposing human treatments for veterinary use. It focuses on tackling life-threatening diseases like pet cancer, feline infectious peritonitis, systemic fungal diseases, and other emerging illnesses.
Anivive’s direct-to-veterinarian sales platform Engage launched in early 2024 and has already processed over 9,000 orders. In total, the company has secured over $80MM in contracts and preorders.
